JP2021536244A5 - - Google Patents
Info
- Publication number
- JP2021536244A5 JP2021536244A5 JP2021511542A JP2021511542A JP2021536244A5 JP 2021536244 A5 JP2021536244 A5 JP 2021536244A5 JP 2021511542 A JP2021511542 A JP 2021511542A JP 2021511542 A JP2021511542 A JP 2021511542A JP 2021536244 A5 JP2021536244 A5 JP 2021536244A5
- Authority
- JP
- Japan
- Prior art keywords
- target rna
- vector according
- vector
- sequence complementary
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862728007P | 2018-09-06 | 2018-09-06 | |
| US62/728,007 | 2018-09-06 | ||
| US201862766433P | 2018-10-17 | 2018-10-17 | |
| US62/766,433 | 2018-10-17 | ||
| US201862773150P | 2018-11-29 | 2018-11-29 | |
| US201862773146P | 2018-11-29 | 2018-11-29 | |
| US62/773,146 | 2018-11-29 | ||
| US62/773,150 | 2018-11-29 | ||
| US201862780241P | 2018-12-15 | 2018-12-15 | |
| US62/780,241 | 2018-12-15 | ||
| PCT/US2019/050095 WO2020051555A1 (en) | 2018-09-06 | 2019-09-06 | Rna and dna base editing via engneered adar recruitment |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021536244A JP2021536244A (ja) | 2021-12-27 |
| JP2021536244A5 true JP2021536244A5 (enExample) | 2022-10-19 |
| JP7720623B2 JP7720623B2 (ja) | 2025-08-08 |
| JP7720623B6 JP7720623B6 (ja) | 2025-09-18 |
Family
ID=69723301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021511542A Active JP7720623B6 (ja) | 2018-09-06 | 2019-09-06 | 遺伝子操作されたａｄａｒのリクルートを介したｒｎａ及びｄｎａ塩基の編集 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20220010333A1 (enExample) |
| EP (2) | EP4332224A3 (enExample) |
| JP (1) | JP7720623B6 (enExample) |
| CN (2) | CN119193702A (enExample) |
| AU (1) | AU2019336793B2 (enExample) |
| CA (1) | CA3110998A1 (enExample) |
| GB (1) | GB2590880A (enExample) |
| WO (1) | WO2020051555A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110612353A (zh) * | 2017-03-03 | 2019-12-24 | 加利福尼亚大学董事会 | 经由抑制性tRNAs和脱氨酶对突变进行RNA靶向 |
| WO2019104094A2 (en) | 2017-11-21 | 2019-05-31 | The Regents Of The University Of California | Fusion proteins and methods for site-directed genome editing |
| CA3136735A1 (en) | 2019-04-15 | 2020-10-22 | Edigene Inc. | Methods and compositions for editing rnas |
| AU2020313143B2 (en) * | 2019-07-12 | 2024-04-04 | Peking University | Targeted RNA editing by leveraging endogenous adar using engineered RNAs |
| WO2021113390A1 (en) * | 2019-12-02 | 2021-06-10 | Shape Therapeutics Inc. | Compositions for treatment of diseases |
| CA3159799A1 (en) * | 2019-12-02 | 2021-06-10 | Prashant MALI | Engineering circular guide rnas |
| US11827880B2 (en) | 2019-12-02 | 2023-11-28 | Shape Therapeutics Inc. | Therapeutic editing |
| IL293671A (en) * | 2019-12-09 | 2022-08-01 | Astellas Pharma Inc | Antisense guide RNA with an additional functional region for target RNA editing |
| CA3173012A1 (en) * | 2020-04-22 | 2021-10-28 | Susan BYRNE | Compositions and methods using snrna components |
| JP2023529316A (ja) * | 2020-05-26 | 2023-07-10 | シェイプ セラピューティクス インコーポレイテッド | ゲノム編集のための組成物及び方法 |
| EP4158019A1 (en) * | 2020-05-26 | 2023-04-05 | Shape Therapeutics Inc. | Methods and compositions relating to engineered guide systems for adenosine deaminase acting on rna editing |
| EP4158017A1 (en) * | 2020-05-26 | 2023-04-05 | Shape Therapeutics Inc. | Engineered circular polynucleotides |
| KR20230035362A (ko) * | 2020-07-06 | 2023-03-13 | 에디진 테라퓨틱스 (베이징) 인크. | 개선된 rna 편집 방법 |
| CN116209762A (zh) * | 2020-07-30 | 2023-06-02 | 阿达尔克斯制药有限公司 | Adar依赖性编辑组合物及其使用方法 |
| CN115989041A (zh) * | 2020-08-24 | 2023-04-18 | 波涛生命科学有限公司 | 经工程化为表达adar1的细胞和非人动物及其用途 |
| WO2022078569A1 (en) * | 2020-10-12 | 2022-04-21 | Eberhard Karls Universität Tübingen | Artificial nucleic acids for rna editing |
| US20230399635A1 (en) * | 2020-11-11 | 2023-12-14 | Shape Therapeutics Inc. | RNA-Editing Compositions and Methods of Use |
| CN116648508A (zh) * | 2020-11-11 | 2023-08-25 | 塑造治疗公司 | Rna编辑组合物和使用方法 |
| EP4256050A4 (en) * | 2020-12-01 | 2025-01-22 | Shape Therapeutics Inc. | High throughput rna-editing screening methods |
| US20240150754A1 (en) * | 2020-12-25 | 2024-05-09 | Astellas Pharma Inc. | Guide rna for editing polyadenylation signal sequence of target rna |
| CA3220338A1 (en) * | 2021-05-25 | 2022-12-01 | Yiannis SAVVA | Engineered guide rnas and polynucleotides |
| US20240279656A1 (en) * | 2021-06-29 | 2024-08-22 | Shape Therapeutics Inc. | Engineered Guide RNAs and Polynucleotides |
| TW202321451A (zh) * | 2021-08-18 | 2023-06-01 | 北京大學 | 工程化的 adar 招募 rnas 及其使用方法 |
| JP2024533163A (ja) | 2021-09-03 | 2024-09-12 | タシト・セラピューティクス・インコーポレーテッド | スプライソソーム構成要素のリクルートを介したｒｎａ編集 |
| JP2023040852A (ja) * | 2021-09-10 | 2023-03-23 | 隆光 矢野 | －１フレームシフトを誘導するための１本鎖核酸分子及び組成物 |
| US20230167441A1 (en) * | 2021-11-30 | 2023-06-01 | Minghong Zhong | Segmented Nucleic Acids |
| US20250115908A1 (en) * | 2022-02-07 | 2025-04-10 | The Regents Of The University Of California | Method of interfering with repetitive rna |
| US20250215426A1 (en) * | 2022-04-05 | 2025-07-03 | Astellas Gene Therapies, Inc. | Compositions and methods for the treatment of muscular dystrophies |
| CN116732039B (zh) * | 2023-08-03 | 2023-11-14 | 呈诺再生医学科技(北京)有限公司 | 一种促进rna序列在细胞内直接环化翻译的序列组合及其应用 |
| CN117210435A (zh) * | 2023-08-29 | 2023-12-12 | 苏州湃芮生物科技有限公司 | 一种用于调控rna甲基化修饰的编辑系统及其应用 |
| CN121059628A (zh) * | 2024-06-03 | 2025-12-05 | 时夕(广州)生物科技有限公司 | 调控RNA剪接的向导agRNA |
| WO2026061377A1 (zh) * | 2024-09-18 | 2026-03-26 | 时夕(广州)生物科技有限公司 | Adar向导rna及其应用 |
| WO2026080897A1 (en) * | 2024-10-11 | 2026-04-16 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of chronic pain |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| FR2764387B1 (fr) * | 1997-06-05 | 1999-07-23 | Centre Nat Rech Scient | Utilisation d'une proteine fluorescente pour la detection d'interactions entre une proteine cible et son ligand |
| BR112014020325A2 (pt) * | 2012-02-17 | 2017-08-08 | Childrens Hospital Philadelphia | composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos |
| AU2015367378A1 (en) * | 2014-12-17 | 2017-06-15 | Proqr Therapeutics Ii B.V. | Targeted RNA editing |
| EP3389671A4 (en) * | 2015-12-14 | 2019-07-17 | Cold Spring Harbor Laboratory | ANTISENSE OLIGOMERS FOR THE TREATMENT OF ALAGILLE SYNDROME |
| AU2017283713B2 (en) * | 2016-06-17 | 2021-04-08 | Massachusetts Institute Of Technology | Type VI CRISPR orthologs and systems |
| EP3475424A1 (en) * | 2016-06-22 | 2019-05-01 | ProQR Therapeutics II B.V. | Single-stranded rna-editing oligonucleotides |
| WO2018208998A1 (en) * | 2017-05-10 | 2018-11-15 | The Regents Of The University Of California | Directed editing of cellular rna via nuclear delivery of crispr/cas9 |
-
2019
- 2019-09-06 CN CN202410647165.1A patent/CN119193702A/zh active Pending
- 2019-09-06 GB GB2104889.7A patent/GB2590880A/en not_active Withdrawn
- 2019-09-06 AU AU2019336793A patent/AU2019336793B2/en active Active
- 2019-09-06 EP EP23214540.9A patent/EP4332224A3/en active Pending
- 2019-09-06 US US17/273,885 patent/US20220010333A1/en not_active Abandoned
- 2019-09-06 JP JP2021511542A patent/JP7720623B6/ja active Active
- 2019-09-06 EP EP19857915.3A patent/EP3847255A4/en not_active Withdrawn
- 2019-09-06 CN CN201980072798.1A patent/CN112996912A/zh active Pending
- 2019-09-06 CA CA3110998A patent/CA3110998A1/en active Pending
- 2019-09-06 WO PCT/US2019/050095 patent/WO2020051555A1/en not_active Ceased
-
2025
- 2025-07-07 US US19/261,672 patent/US20260092292A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Smeyne et al. | Infection and risk of Parkinson’s disease | |
| Pleasure et al. | The spectrum of neurologic disease in the severe acute respiratory syndrome coronavirus 2 pandemic infection: neurologists move to the frontlines | |
| Kiyota et al. | FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer's disease and has therapeutic implications for neurocognitive disorders | |
| JP2019089787A5 (enExample) | ||
| BR112022015979A2 (pt) | Vetores de terapia genética para tratamento de doenças cardíacas | |
| RU2016123086A (ru) | Способы и композиции для лечения болезни хантингтона | |
| MX2021012867A (es) | Terapéutica de anticuerpos postraduccionalmente modificados completamente humanos. | |
| CL2020000728A1 (es) | Variantes de cápsides de virus adenoasociados y métodos de uso de estas. | |
| JP2014076062A5 (enExample) | ||
| JPWO2019156137A5 (enExample) | ||
| JP2022066336A5 (enExample) | ||
| JP2019525898A5 (enExample) | ||
| JP2016538885A5 (enExample) | ||
| FI4342992T3 (fi) | Geenihoito neurodegeneratiivisiin sairauksiin | |
| JP2014504866A5 (enExample) | ||
| JP2019520344A5 (enExample) | ||
| WO2020219766A8 (en) | Compositions useful in treatment of rett syndrome | |
| MX2023003810A (es) | Composiciones de arn de interferencia (arni) de alfa sinucleina (snca) y metodos de usos de las mismas para tratar o prevenir enfermedades neurodegenerativas asociadas con la snca. | |
| JP2019531293A5 (enExample) | ||
| WO2023244276A3 (en) | DNA ENCODED ANTIBODIES WITH Fc MODIFICATIONS | |
| Shojaeefar et al. | The possible double‐edged sword effects of vitamin D on COVID‐19: A hypothesis | |
| JP2019505567A5 (enExample) | ||
| Wang et al. | The roles of lncRNAs in Th17-associated diseases, with special focus on JAK/STAT signaling pathway | |
| JP2020517268A5 (enExample) | ||
| WO2023169115A9 (zh) | 一种神经系统高亲和性的aav载体及其应用 |